Skip to content

NASCENT BIOTECH, INC.: financial reference

Explore NASCENT BIOTECH, INC. financial histories from SEC filings, with original units, reporting periods, filing dates and downloadable source data.

Filing record ends 2024-07-01

The latest filing in this captured record is a 10-K filed 2024-07-01. No later filing is in the SEC companyfacts record captured on 2026-09-22. NASCENT BIOTECH, INC. may have stopped filing, merged, or changed its reporting entity; nothing on this page describes its current status. Values are as reported at the time.

Reported financial histories

Choose a measure to inspect its definition, complete selected history and filing provenance. Each row shows the latest period available for that selected concept and original unit. Separate currencies and reporting intervals remain separate rows. Coverage dates can differ between concepts. A recent capture does not imply recent accounting coverage; these amounts are not prices.

Latest periods by selected concept and original unit
MeasurePeriod startPeriod endValueUnitFiled
Total assets-2024-03-31552,120USD2024-07-01
Total liabilities-2024-03-31808,794USD2024-07-01
Stockholders equity-2024-03-31-256,674USD2024-07-01
Cash and cash equivalents-2020-03-313,218USD2021-07-08
Net income or loss2023-04-012024-03-31-2,087,682USD2024-07-01
Operating cash flow2023-04-012024-03-31-1,186,066USD2024-07-01
Revenue2022-04-012023-03-310USD2023-07-03
Financing cash flow2023-04-012024-03-311,386,000USD2024-07-01
Retained earnings or deficit-2024-03-31-24,260,457USD2024-07-01
Basic weighted-average shares2017-04-012018-03-3125,883,774shares2018-06-29
Diluted weighted-average shares2017-04-012018-03-3125,883,774shares2018-06-29
Basic earnings per share2017-04-012018-03-31-0.09USD/shares2018-06-29
Diluted earnings per share2017-04-012018-03-31-0.09USD/shares2018-06-29
Income tax expense or benefit2023-04-012024-03-310USD2024-07-01
Share-based compensation expense2023-04-012024-03-3160,850USD2024-07-01
Operating income or loss2023-04-012024-03-31-2,229,879USD2024-07-01
Current assets-2024-03-31552,120USD2024-07-01
Interest expense2023-04-012024-03-31385,236USD2024-07-01
Current liabilities-2024-03-31808,794USD2024-07-01
Current accounts payable-2020-03-31852,664USD2020-06-22
Net current accounts receivable-2022-03-310USD2022-06-15
Operating expenses2023-04-012024-03-312,229,879USD2024-07-01
Selling, general and administrative expense2017-04-012018-03-311,027,141USD2018-06-29
Research and development expense2023-04-012024-03-31110,975USD2024-07-01
Common shares outstanding-2024-03-31170,594,165shares2024-07-01
Cash including restricted cash-2024-03-31372,120USD2024-07-01
Additional paid-in capital-2024-03-3123,833,189USD2024-07-01
Total equity including noncontrolling interests-2018-03-31-86,379USD2018-06-29
Prepaid expenses and other current assets-2023-03-3182,816USD2023-07-03
Pre-tax income or loss from continuing operations2019-04-012020-03-31-4,004,153USD2020-06-22
Profit or loss including noncontrolling interests2023-04-012024-03-31-2,087,682USD2024-07-01
General and administrative expense2023-04-012024-03-31403,589USD2024-07-01
Depreciation expense2022-04-012023-03-310USD2023-07-03
Other nonoperating income or expense2023-04-012024-03-31142,197USD2024-07-01
Interest paid, net2023-04-012024-03-310USD2024-07-01
Proceeds from issuing common stock2023-04-012024-03-311,561,000USD2024-07-01
Change in accounts receivable2023-04-012024-03-310USD2024-07-01

Filings

40 NASCENT BIOTECH, filings with published measures: what each annual or quarterly report tagged, with the periods it covered, as reported in that filing. The histories above show the latest-filed value per period.

Inspect the source

Entity
NASCENT BIOTECH, INC. / CIK 0001622057
Captured
SEC response SHA-256
95dd35525b286efc227d01e79a7497c1e5ad706dcc5db0f6b86a7f03d8b13612

Current SEC company facts · Download the original response snapshot (gzip) · Download the selected JSON

Latest-filed annual-report facts per unit and reporting period at capture time. Duration facts cover 300 to 400 days. This selection can include restatements and is not a point-in-time backtest dataset. Missing concepts are omitted, never zero-filled. Values retain original units and are not currency converted. Extended concepts require compatible unit shapes and at least three reporting ends with changing values within one unit. Constant or incompatible added histories are omitted.

Public company accounting reference, not market prices, returns, an investment recommendation, or ALPHAC performance. Validate a separately constructed return series with the validation API; accounting values are not returns.

Use this in research

A financial period ends before its results become public. Use the filing date as a minimum availability boundary, inspect amendments, and retain the original filing vintage when testing historical signals. This latest-filed selection can contain information unavailable at the time.

These pages do not supply prices, total-return histories, corporate-action adjustments or a tradable universe. Build those inputs separately before evaluating a strategy. A profitable backtest can still reflect selection bias or costs that were left out.

Research methodology · Execution and cost assumptions · Check backtest overfitting

Build with the open-source tools

Use these accounting records as inspectable inputs. When you have constructed a return series, the validation tools can help test its statistical evidence and preserve the result with its limitations.

Read the published dataset with Python
import json
from urllib.request import urlopen

with urlopen("https://canlicapital.com/company-data/0001622057.json") as response:
    record = json.load(response)
print(record["fetched_at"])
print(record["policy"])
for concept in record["concepts"]:
    print(concept["tag"], next(iter(concept["observations"])))